- Home
- » Tags
- » CETP inhibitor
Top View
- PCSK9 Inhibitor Monoclonal Antibodies for the Treatment of Hypercholesterolemia Authors: Sarah Ndegwa, Michel Boucher, and Monika Mierzwinski-Urban
- Prevention of Murine Atherosclerosis with Bempedoic Acid
- (PCSK9) Antibodies, DS-9001A, Albumin Binding Domain–Fused Anticalin Protein S
- Beyond the Statin Therapy
- (12) United States Patent (10) Patent No.: US 6,569,905 B1 Sikorski Et Al
- Treatment of Dyslipidaemia in Children
- Anacetrapib, a New CETP Inhibitor: the New Tool for the Management of Dyslipidemias?
- ACC 2019 Preview – Amarin and Esperion Look for an Edge
- The End of the Road for CETP Inhibitors After Torcetrapib? Tisha Joy and Robert A
- CARDIOVASCULAR PRODUCTS FOCUS Category Leaders, Ranked by US Sales
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: a Systematic Review and Meta-Analysis
- Effects of the CETP Inhibitor Evacetrapib Administered As Monotherapy Or in Combination with Statins on HDL and LDL Cholesterol a Randomized Controlled Trial
- Newer Cholesterol-Lowering Agents: What You Must Know
- Niacin Mechanism of Action Thomas Dayspring MD, FACP
- Novel New Therapeu.Cs for Atherosclero.C Cardiovascular Disease
- Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients with Coronary Heart Disease
- Lipid Modification to Reduce Cardiovascular Risk
- University of Groningen Emerging Small Molecule Drugs Colin, Sophie